R. Lorenzon

Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial.

BACKGROUND Type 1 diabetes results from immune-mediated destruction of pancreatic β cells, driven partly by regulatory T-cell (Treg) insufficiency. We previously showed that low-dose interleukin-2 (IL-2) selectively activates Tregs in people with type 1 diabetes. We aimed to evaluate the efficacy of low-dose IL-2 in pr...

Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases.

OBJECTIVES Low-dose interleukin-2 (IL-2LD) preferentially stimulates regulatory T cells (Treg) over conventional CD4+ T cells (Tconv), controlling inflammation and promoting immune tolerance in autoimmune and other immune-mediated inflammatory diseases. However, IL-2 has pleiotropic functions, and its therapeutic mecha...

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease